Azilect tablets are taken by mouth once daily, with or without food, for Parkinson’s Disease. They may be prescribed alone or alongside levodopa to help control movement symptoms. The amount per…
Azilect tablets are taken by mouth once daily, with or without food, for Parkinson’s Disease. They may be prescribed alone or alongside levodopa to help control movement symptoms. The amount per intake is selected individually according to the treatment plan and response.
Azilect belongs to the monoamine oxidase type B inhibitor group. Its recognised active substance is rasagiline mesylate. Rasagiline reduces the activity of monoamine oxidase B, an enzyme involved in dopamine breakdown.
Azilect is used in the management of Parkinson’s Disease, a progressive neurological condition involving reduced dopamine signalling in areas of the brain that coordinate movement. It may support treatment when symptoms include slowness, muscular rigidity, tremor, or difficulty initiating movement.
This can increase the availability and duration of dopamine activity in the brain.
The medicine may be prescribed as monotherapy during earlier treatment or as adjunctive therapy with levodopa when symptom control requires additional support. The European Medicines Agency describes this therapeutic role for Parkinson’s Disease, including use alongside levodopa in patients experiencing motor fluctuations [1].
Rasagiline mesylate acts within the central nervous system rather than directly relaxing muscles or replacing dopamine in tablet form. By slowing dopamine metabolism, it can help preserve dopaminergic signalling between nerve cells.
The response is gradual. Azilect does not stop Parkinson’s Disease from progressing and does not replace specialist assessment when symptoms change. Its purpose is symptom management, with treatment decisions based on movement control, adverse effects, daily functioning, and any concurrent medicines.
One practical detail is easy to miss: symptom improvement may be subtle at first. Patients may notice easier movement, less morning stiffness, or longer periods when levodopa is working rather than a sudden dramatic change.
Monoamine oxidase B contributes to dopamine breakdown in the brain. Rasagiline inhibits this enzyme, allowing dopamine signalling to remain available for longer. The effect complements levodopa, which is converted into dopamine in the brain.
Azilect and levodopa work through different but related pathways:
| Treatment approach | Main pharmacological role | Typical clinical use |
|---|---|---|
| Azilect alone | Slows dopamine breakdown | Earlier Parkinson’s Disease or milder symptoms |
| Azilect with levodopa | Supports existing dopaminergic treatment | Motor symptoms or fluctuations requiring added control |
| Dopamine-replacement therapy | Supplies a precursor converted into dopamine | More pronounced movement impairment |
This distinction helps explain why a neurologist may keep Azilect in the regimen when levodopa is introduced. The medicines are not interchangeable, and combining therapies can require observation for excessive involuntary movements, dizziness, sleepiness, or changes in blood pressure.
Clinical practice focuses on function rather than a single symptom score. A useful treatment response may mean more reliable walking, easier dressing, improved handwriting, or fewer periods when movement becomes markedly slow. The same regimen can affect two people differently. Follow-up also considers whether benefits last across the day. Patients should report changes in mobility, sleep, or alertness between visits.
Azilect is not intended to provide immediate relief during a sudden “off” episode. Its pharmacological effect depends on regular use and continued enzyme inhibition. Abrupt changes to Parkinson’s treatment can destabilise symptom control.
Azilect is taken orally as a tablet once daily. It may be taken with food or on an empty stomach. The amount per intake is selected individually rather than being one fixed number for every person.
Doctors may use Azilect in two main ways:
A physician may adjust the wider Parkinson’s regimen if Azilect is added to levodopa. The response is assessed through movement quality, wearing-off periods, dyskinesia, falls, dizziness, and daily activities.
Azilect tablets should be swallowed as prescribed. Do not change the daily amount, stop treatment suddenly, or add another Parkinson’s medicine without a specific treatment decision.
Food is permitted, but very large amounts of tyramine-rich food may require discussion with the prescriber because monoamine oxidase inhibition can alter blood-pressure responses. The risk is lower with selective monoamine oxidase type B inhibition than with non-selective MAO inhibition, yet dietary and medicine history still matters.
Azilect differs from levodopa because it slows dopamine breakdown rather than supplying a dopamine precursor. It also differs from dopamine agonists, which stimulate dopamine receptors directly. These approaches may be used separately or together according to the pattern of Parkinson’s symptoms.
| Approach | Main action | Main limitation |
|---|---|---|
| Azilect | Inhibits dopamine breakdown through MAO-B | May not control advanced symptoms alone |
| Levodopa | Provides a precursor converted to dopamine | Long-term treatment may involve wearing-off or dyskinesia |
| Dopamine agonist | Stimulates dopamine receptors | Can cause sleepiness, hallucinations, swelling, or impulse-control problems |
Azilect may be attractive within a treatment plan when a clinician wants to support dopamine activity without immediately increasing levodopa exposure. Its limitations include the possibility of insufficient symptom control when Parkinson’s Disease has become more advanced.
Levodopa often provides stronger improvement in bradykinesia and rigidity, yet its dose may become harder to balance as the disease and treatment duration progress. Dopamine agonists can help selected patients but may be unsuitable for people with problematic sleepiness, hallucinations, cognitive impairment, or impulse-control symptoms.
There is no single preferred approach for every patient. Neurologists weigh motor benefit against sleep, blood pressure, cognition, falls, psychiatric symptoms, and the practical demands of daily dosing. NICE guidance supports an individualised approach to Parkinson’s treatment rather than a uniform sequence for every adult [2].
Several everyday errors can reduce treatment benefit or increase avoidable risk:
One patient-level detail matters with combination therapy: improvement in stiffness can occur alongside more troublesome involuntary movements. A person may describe the treatment as “working better” while also needing a dose adjustment because dyskinesia has increased.
Another frequent issue is under-reporting sleepiness. Falling asleep during television may seem minor, but sudden sleep during driving or conversation is a meaningful safety signal.
Treatment may be ruled out or require specialist reassessment in the following circumstances:
Azilect must not be combined casually with antidepressants. Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and other serotonergic medicines may create interaction concerns. The FDA prescribing information warns about potentially serious reactions involving agitation, confusion, sweating, fever, muscle rigidity, and changes in blood pressure [3].
The combination with sympathomimetic medicines also deserves review. Some nasal decongestants, stimulants, and weight-loss products can increase blood pressure or heart rate. Herbal products and non-prescription sleep remedies should be disclosed because “natural” does not mean interaction-free.
Very high tyramine intake can provoke headache or a rise in blood pressure in susceptible people. Aged cheeses, cured meats, fermented foods, and yeast extracts are examples that may need moderation, especially if large quantities are consumed together.
Azilect is NOT for you if severe liver impairment or a contraindicated interaction is present.
Azilect should not be stopped abruptly without a planned medical decision. Parkinsonian symptoms can worsen when dopaminergic treatment is withdrawn suddenly, and the person may become less mobile or more vulnerable to falls.
Azilect can cause adverse effects involving the nervous system, circulation, gastrointestinal tract, and sleep pattern. The likelihood depends on whether it is used alone or with levodopa.
Reported effects may include:
A person who feels light-headed after standing should sit or lie down promptly. Orthostatic hypotension can increase fall risk, especially in people already affected by balance problems. Slow position changes can help, but persistent dizziness requires treatment review.
Rasagiline may also be associated with somnolence or sudden sleep episodes. Driving, cycling in traffic, and operating machinery become unsafe if unexpected sleepiness occurs. This issue deserves direct discussion because a patient may interpret fatigue as part of Parkinson’s Disease rather than as a medicine-related effect.
Hallucinations, severe confusion, fainting, marked agitation, or rapidly worsening involuntary movements require prompt medical assessment. These symptoms can reflect the combined effect of Parkinson’s Disease, Azilect, levodopa, or another medicine.
One practical distinction matters: dyskinesia may increase after dopaminergic treatment is intensified. If involuntary movements become more frequent after Azilect is added to levodopa, the solution may involve adjusting the levodopa regimen rather than simply stopping Azilect.
In clinical practice, neurologists judge Azilect by changes in daily function rather than by the presence or absence of one symptom. A patient may report smoother mornings, fewer delayed movements, or more predictable benefit from levodopa.
The medicine tends to fit best within a structured treatment plan. Doctors usually ask about walking, falls, stiffness, tremor, involuntary movements, sleep, hallucinations, blood pressure, and daytime alertness at follow-up visits.
A common mistake is expecting Azilect to act like an emergency treatment. Its role is maintenance therapy. The goal is steadier control over time, not an immediate reversal of a sudden off period.
Clinicians also pay attention to the person’s environment. A patient who drives, works at height, cares for children, or lives alone may face greater consequences from sleep attacks, dizziness, or confusion. Treatment decisions therefore include safety and function, not only neurological examination findings.
A 2009 clinical trial indexed in PubMed examined rasagiline as a component of Parkinson’s Disease management, while treatment selection still requires attention to disease stage and adverse effects [4].
Severe liver impairment is a major condition that can rule out Azilect because rasagiline is processed through the liver. The European Medicines Agency product information identifies severe hepatic impairment as a contraindication and advises caution in less severe hepatic disease. This remains a relevant safety point in 2026 for people with chronic liver disease or abnormal liver tests.
Alcohol can worsen dizziness, sleepiness, impaired balance, and blood-pressure changes associated with Parkinson’s Disease treatment. The WHO’s The WHO Parkinson disease fact sheet (2023) identifies impaired movement and falls as important concerns, so alcohol can add to safety risks. Alcohol may also make it harder to recognise whether fatigue or poor coordination comes from Azilect, levodopa, or the drink itself.
Azilect can be taken once daily with or without food, so the best time is usually the part of the day that supports consistent use. Morning administration may suit people who already take other Parkinson’s medicines at breakfast, while another time may be chosen around sleepiness or the wider regimen. EMA product information from 2015 supports once-daily administration, with the exact schedule individualised in clinical practice.
A missed dose should be skipped if the next scheduled dose is approaching, rather than replaced with two tablets together. The FDA Azilect Prescribing Information (2020) supports following the prescribed schedule and avoiding dose changes without medical advice. Repeated missed doses should be mentioned during treatment review because irregular administration can make symptom patterns harder to interpret.
Azilect is not routinely used in children or adolescents because Parkinson’s Disease treatment evidence and regulatory indications apply to adults. The EMA product information does not establish routine paediatric use. A 2026 treatment decision for anyone under 18 would require a specialist assessment of the diagnosis, alternative causes of movement symptoms, and the evidence for the proposed regimen.
Azilect should be swallowed in the prescribed manner rather than crushed or chewed unless a clinician has specifically approved another method. The FDA Azilect Prescribing Information (2020) describes oral tablet administration and does not support changing the tablet form to create an unplanned dose alteration. Splitting can also make the amount taken less reliable when the tablet is not designed to provide equal halves.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
